Difference between revisions of "Camrelizumab (AiRuiKa)"
m |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Esophageal squamous cell carcinoma]] | *[[Esophageal squamous cell carcinoma]] | ||
| + | *[[Hepatocellular carcinoma]] | ||
*[[Nasopharyngeal carcinoma]] | *[[Nasopharyngeal carcinoma]] | ||
| Line 18: | Line 19: | ||
[[Category:Esophageal squamous cell carcinoma medications]] | [[Category:Esophageal squamous cell carcinoma medications]] | ||
| + | [[Category:Hepatocellular carcinoma medications]] | ||
[[Category:Nasopharyngeal carcinoma medications]] | [[Category:Nasopharyngeal carcinoma medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] | ||
Revision as of 22:41, 1 May 2022
Mechanism of action
From the NCI Drug Dictionary: A monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1,) with immune checkpoint inhibitory and antineoplastic activities. Upon administration, camrelizumab binds to and blocks the binding of PD-1, expressed on activated T lymphocytes, B cells and natural killer (NK) cells, to its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on antigen presenting cells (APCs). This prevents the activation of PD-1 and its downstream signaling pathways. This restores immune function through the activation of cytotoxic T lymphocytes (CTLs) and cell-mediated immune responses against tumor cells or pathogens.
Toxicity management
Diseases for which it is used
Also known as
- Code names: HR-301210, SHR-1210
- Brand name: AiRuiKa